Nabriva Therapeutics (NBRV) Competitors

Nabriva Therapeutics (NASDAQ:NBRV) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.

Does the media refer more to NBRV or PRME?

In the previous week, Prime Medicine had 19 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 20 mentions for Prime Medicine and 1 mentions for Nabriva Therapeutics. Prime Medicine's average media sentiment score of 0.02 beat Nabriva Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nabriva Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders believe in NBRV or PRME?

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 23.5% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has higher valuation & earnings, NBRV or PRME?

Nabriva Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Prime Medicine	$3.85M	39.77	-$198.13M	-$1.61	-0.72

Which has more risk and volatility, NBRV or PRME?

Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

Do analysts prefer NBRV or PRME?

Prime Medicine has a consensus price target of $11.80, suggesting a potential upside of 912.88%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Prime Medicine	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Does the MarketBeat Community favor NBRV or PRME?

Nabriva Therapeutics received 363 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 65.22% of users gave Prime Medicine an outperform vote while only 54.28% of users gave Nabriva Therapeutics an outperform vote.

Company	Underperform	Outperform
Nabriva Therapeutics	Outperform Votes 393 54.28%	Underperform Votes 331 45.72%
Prime Medicine	Outperform Votes 30 65.22%	Underperform Votes 16 34.78%

Is NBRV or PRME more profitable?

Prime Medicine has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Prime Medicine's return on equity of -107.87% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Prime Medicine	N/A	-107.87%	-74.97%

Summary

Prime Medicine beats Nabriva Therapeutics on 14 of the 18 factors compared between the two stocks.